This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of effectiveness appears to have been based on treatment completers only. However, almost the full sample of women initially included in the study was considered in the final analysis (n=232 or 99%). The primary health outcomes were:
LNG-IUS and hysterectomy outcomes; QoL, measured using the 5D-EuroQol (EQ-5D) and the Rand-36 scale; general health, measured by a visual analogue scale; anxiety; depression; and sexuality-related aspects.
Laboratory tests, such as the measurement of menstrual blood loss (MBL) and blood haemoglobin concentration, were also evaluated. The baseline comparability of the study groups was not discussed.
Effectiveness results
In the LNS-IUS group, at the end of follow-up, 57 (48%) women (of whom 8 had a replacement LNG-IUS) had the LNG-IUS in situ and 10 (8%) were without LNG-IUS (of whom 1 had had thermoablation). Of the 57 women with the LNG-IUS in situ, 43 (75%) reported amenorrhoea or oligomenorrhoea, 11 (19%) reported irregular bleeding, and 3 (6%) reported scanty regular bleeding.
Hysterectomy was performed in 50 women (42%). Fifteen (30%) of these 50 women developed complications.
Among the 60 women who did not continue treatment with the LNG-IUS, the reason for removing the LNG-IUS was intermenstrual bleeding in 42 women (70%), heavy bleeding in 19 (32%), and hormonal symptoms in 18 (30%). Some women had more than one complaint.
In the hysterectomy group, 109 of the 117 women underwent hysterectomy, including 2 who had the surgery 12 months after randomisation.
Three bladder perforations and one bowel perforation were included in the intraoperative complications.
Postoperative complications occurred in 33 (30%) women.
Overall satisfaction was high with both treatments. The proportion of women who were satisfied or very satisfied was 94% in the LNG-IUS group and 93% in the hysterectomy group.
EQ-5D scores improved in both groups compared with baseline values (LNG-IUS group, p=0.002; hysterectomy group, p=0.001), with no substantial difference between the groups. In both groups, QoL measured by the RAND-36 questionnaire improved significantly in all dimensions except physical functioning.
General health status, as measured by a visual analogue scale, was significantly improved in the hysterectomy group, (p=0.04), but not in the LNG-IUS group, (p=0.08). However, no substantial difference between the groups was found.
The anxiety and depression scores also improved significantly, with no substantial difference between the groups. Sexual function scores showed no substantial within-or between-group changes, except that participant satisfaction with the partner declined in the LNG-IUS group, (p=0.006).
MBL was measured in 227 women at baseline. Objective menorrhagia (i.e. MBL =/> 80 mL) was present in 132 (58%) women. At 5 years, only 4 of 57 women with LNG-IUS in situ who had bleeding (out of 11 having irregular bleeding and 3 having regular scanty bleeding) contributed samples for MBL.
Blood haemoglobin and serum ferritin concentrations were comparable between the groups.
Clinical conclusions
The effectiveness analysis showed that similar outcomes were observed between the groups. Thus, the two interventions were considered equivalent.
Measure of benefits used in the economic analysis
The clinical outcomes and QoL scores were equivalent between the groups, thus no summary benefit measure was used in the economic evaluation. In effect, a cost-minimisation analysis was carried out.
Direct costs
The analysis of the costs took a societal perspective. The direct medical costs included were hospital services (operations, inpatient days, procedures and outpatient visits), travel and medications. The unit costs were presented separately from the quantities of resources used for most items. Resource consumption was mainly estimated using data obtained from medical records and self-reported data. The quantities of resources used referred to the sample of patients included in the clinical trial. The time horizon of the analysis was 5 years and, in general, data from medical records and questionnaires were available for the first and the last year of the study. To calculate costs for years 2 to 4, cost data were taken from questionnaires for the last year and these data were used to calculate an average cost. The average cost was then multiplied by 4 and added to the cost for the first year. The hospital costs were derived from a system of pricing based on diagnosis-related groups at Helsinki University Hospital. The primary care costs were calculated from the unit costs of these services in the Helsinki Occupational Health Care Centers. The costs were gathered in 1996 and 2001. The costs assessed in 2001 were discounted at an annual rate of 3%. The price year was 1996.
Statistical analysis of costs
No statistical analyses of the costs were performed. The costs were presented as average values with 95% confidence intervals (CIs).
Indirect Costs
The indirect costs (i.e. sick leave days as productivity losses) were included in the analysis because a societal perspective was adopted. The unit costs were presented separately from the quantities of resources used. Days of sick leave came for the sample of patients enrolled in the clinical trial. The costs were estimated using the average daily gross wage for women in Finland, which included social security contributions. The price year was 1996. An annual discount rate of 3% was applied.
Currency
Finnish markkaa (FIM). FIM were converted to US dollars ($) using purchasing power parities in 1996 at the following rate: $1 = FIM 5.89.
